Invasive fungal infections – Page 4

Invasive Rhinocerebral Mucormycosis Is a Rare Complication in Systemic Juvenile Idiopathic Arthritis Patient

mycolabadmin

A 5-year-old girl with systemic juvenile arthritis being treated with immunosuppressive medications developed a rare and serious fungal infection in her nose and sinuses caused by a mold called Lichtheimia. The infection caused tissue death and spread toward her brain, but was successfully treated with combination antifungal drugs and surgery. This case highlights how powerful immunosuppressive treatments for severe arthritis can increase the risk of life-threatening fungal infections.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections are becoming a major health threat, affecting over a billion people worldwide. The main problems are difficulty diagnosing these infections, increasing resistance to current medications, and limited treatment options. Doctors and the public need better awareness, and new antifungal drugs with different approaches are needed to effectively treat resistant infections.

Time- and temperature-dependent Pentraxin 3 stability in serum and bronchoalveolar lavage fluid samples

mycolabadmin

Researchers tested how stable Pentraxin 3, a protein marker for fungal infections, remains when stored under different conditions. They found that samples stored in freezers at −20°C or −80°C kept stable for months, making Pentraxin 3 a reliable marker for diagnosing serious fungal infections. However, samples stored at warm temperatures degraded quickly, so proper cold storage is essential for accurate test results.

Schizophyllum radiatum: An uncommon culprit of invasive fungal rhinosinusitis in an immunocompetent patient – A case report from India

mycolabadmin

A 32-year-old healthy woman in India developed a serious fungal infection in her sinuses caused by an unusually rare fungus called Schizophyllum radiatum. Doctors removed the infected material through surgery and identified the fungus using genetic sequencing when standard methods failed. Treatment with antifungal medication successfully cleared the infection, and the patient fully recovered.

Assessing Diagnostic Capabilities and Treatment Accessibility for Invasive Fungal Infections in the Balkan Region

mycolabadmin

Researchers surveyed medical centers across 12 Balkan countries to understand how well-equipped they are to diagnose and treat serious fungal infections. They found that while most centers have basic laboratory tools like microscopes and cultures, advanced molecular tests for identifying fungal species are less common. Antifungal medications like triazoles are widely available, but other important treatment options are harder to find in the region.

A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile

mycolabadmin

Researchers in Chile studied serious mold infections in 176 hospitalized patients (adults and children) over two years. They found that aspergillosis (a lung infection caused by Aspergillus mold) was the most common, especially in patients whose immune systems were compromised by cancer, transplants, or medications. Interestingly, nearly 40% of cases also involved COVID-19 infection. Although almost all patients received antifungal medications, survival rates were concerning, with about one-third of patients still alive after six months.

Introduction to XIV updating course of antimicrobials and infectious diseases

mycolabadmin

Healthcare professionals gathered at a major conference in Madrid to learn about the latest advances in treating infections caused by antibiotic-resistant bacteria and other pathogens. The course highlighted new antibiotic combinations that work against previously untreatable infections, faster ways to identify infections in emergency rooms and intensive care units, and modern treatment strategies based on scientific evidence. Speakers emphasized the importance of using antibiotics wisely, using personalized medicine approaches, and collaborating between laboratory scientists and clinicians to improve patient outcomes.

Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review

mycolabadmin

This study examines rare fungal infections in patients with Chronic Granulomatous Disease, a genetic disorder affecting the immune system. Researchers found that these patients develop various unusual fungal infections despite taking preventive antifungal medications. The infections are difficult to diagnose, often requiring surgical procedures, but can sometimes be cured through stem cell transplantation combined with intensive antifungal treatment.

First case of invasive Rasamsonia argillacea in a child with chronic granulomatous disease in Qatar

mycolabadmin

A 16-year-old girl with a rare immune system disorder called chronic granulomatous disease developed a serious fungal infection caused by Rasamsonia argillacea, a fungus that is not commonly seen in clinical practice. The infection presented as a painful collection in her chest wall that required surgery and multiple antifungal medications. This is the first reported case of this particular fungal infection in the Arabian Peninsula, and successful treatment required a combination of drugs chosen based on laboratory testing of the fungus’s resistance patterns.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common due to new cancer treatments and other medical advances, while some fungal species are developing resistance to standard antifungal medications. The good news is that several new antifungal drugs are in development with better safety profiles and novel mechanisms to fight these infections. However, the field faces challenges including limited specialized mycologists and difficulty designing clinical trials to properly test new treatments.

Research Topic: Invasive fungal infections